Laura Joszt

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among Black patients compared with clinical trials.

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

Experts discussed the great advances and innovations they've seen this year in acute myeloid leukemia (AML) and multiple myeloma.

Demonstrating improvements in patient quality of life using patient-reported outcomes are important for treatments for myeloproliferative neoplasms (MPNs), said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center.

The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.

Key Takeaways Innovations in cancer care are overshadowed by financial concerns, with high out-of-pocket costs limiting access to essential services.

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.

Histotripsy is a new, FDA-approved, minimally invasive technique that destroys liver tumors using high-frequency ultrasound waves.

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.